- Home
- CELC vs URGN Comparison
CELC vs URGN Comparison
Compare CELC & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- URGN
- Stock Information
- Founded
- CELC 2011
- URGN 2004
- Country
- CELC United States
- URGN United States
- Employees
- CELC N/A
- URGN N/A
- Industry
- CELC Medical Specialities
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- CELC Health Care
- URGN Health Care
- Exchange
- CELC Nasdaq
- URGN Nasdaq
- Market Cap
- CELC 440.7M
- URGN 465.9M
- IPO Year
- CELC 2017
- URGN 2017
- Fundamental
- Price
- CELC $13.15
- URGN $10.08
- Analyst Decision
- CELC Strong Buy
- URGN Strong Buy
- Analyst Count
- CELC 6
- URGN 6
- Target Price
- CELC $30.17
- URGN $42.25
- AVG Volume (30 Days)
- CELC 184.2K
- URGN 308.1K
- Earning Date
- CELC 03-26-2025
- URGN 03-13-2025
- Dividend Yield
- CELC N/A
- URGN N/A
- EPS Growth
- CELC N/A
- URGN N/A
- EPS
- CELC N/A
- URGN N/A
- Revenue
- CELC N/A
- URGN $89,363,000.00
- Revenue This Year
- CELC N/A
- URGN $12.17
- Revenue Next Year
- CELC N/A
- URGN $44.23
- P/E Ratio
- CELC N/A
- URGN N/A
- Revenue Growth
- CELC N/A
- URGN 15.64
- 52 Week Low
- CELC $10.35
- URGN $9.78
- 52 Week High
- CELC $22.19
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- CELC 60.85
- URGN 40.55
- Support Level
- CELC $12.55
- URGN $9.86
- Resistance Level
- CELC $13.25
- URGN $11.87
- Average True Range (ATR)
- CELC 0.68
- URGN 0.50
- MACD
- CELC 0.14
- URGN -0.04
- Stochastic Oscillator
- CELC 85.79
- URGN 10.95
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.